Rocket Pharmaceuticals to Sell PRV for $180M
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, payable at closing. The voucher was granted after FDA accelerated approval of KRESLADI, Rocket’s gene therapy for severe LAD-I.
Rocket states that monetizing the voucher provides meaningful non-dilutive capital and extends its cash runway into the second quarter of 2028. The company plans to use the proceeds to support its prioritized cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.
Positive
- $180 million PRV monetization delivers substantial non-dilutive cash proceeds, directly strengthening Rocket’s balance sheet without issuing new equity.
- Cash runway extended into Q2 2028, providing a longer funding horizon to advance Rocket’s cardiovascular gene therapy programs, including clinical-stage assets in Danon disease, PKP2-ACM and BAG3-DCM.
Negative
- None.
Insights
$180M PRV sale adds non-dilutive cash and lengthens Rocket’s funding runway.
Rocket Pharmaceuticals is monetizing its Rare Pediatric Disease Priority Review Voucher for $180 million in cash. Because the voucher can be sold without issuing new shares, this represents non-dilutive capital that directly strengthens Rocket’s balance sheet.
Management highlights that the transaction extends Rocket’s cash runway into the second quarter of 2028. That timeframe supports continued development of its cardiovascular gene therapy pipeline, including clinical programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy, all of which target inherited cardiomyopathy subtypes.
The agreement includes customary representations, warranties, covenants and closing conditions, including Hart-Scott-Rodino clearance. Actual benefit to shareholders will depend on successful closing and Rocket’s execution across its prioritized programs and planned clinical and regulatory milestones described in its forward-looking statements.
8-K Event Classification
3 items: 1.01, 7.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
PRV sale price: $180 million cash
Cash runway: Into Q2 2028
Regulatory basis for PRV: FDA accelerated approval
+2 more
5 metrics
PRV sale price
$180 million cash
Consideration for Rare Pediatric Disease Priority Review Voucher
Cash runway
Into Q2 2028
Pro forma funding horizon after PRV monetization
Regulatory basis for PRV
FDA accelerated approval
Voucher granted following KRESLADI approval for severe LAD-I
Closing condition
HSR waiting period
Expiration or termination required under Hart-Scott-Rodino Act
Runway extension statement
“extends our cash runway into Q2 2028”
Management commentary on impact of PRV monetization
Key Terms
Rare Pediatric Disease Priority Review Voucher, accelerated approval, Hart-Scott-Rodino Antitrust Improvements Act of 1976, gene therapy, +2 more
6 terms
Rare Pediatric Disease Priority Review Voucher regulatory
"pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher"
A rare pediatric disease priority review voucher is a transferable regulatory benefit awarded to a company that wins approval for a drug treating a serious but uncommon childhood illness. It works like a “fast-pass” with regulators: the holder can use it to get an accelerated review of a future drug application or sell the voucher to another company, often for a large sum. Investors care because it can speed time to market or generate immediate cash, boosting potential returns and lowering risk on other programs.
accelerated approval regulatory
"The PRV was awarded following the U.S. Food and Drug Administration (FDA) accelerated approval of KRESLADI"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
Hart-Scott-Rodino Antitrust Improvements Act of 1976 regulatory
"including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"
gene therapy medical
"an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients"
Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.
cash runway financial
"extends our cash runway into the second quarter of 2028"
Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.
non-dilutive capital financial
"PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline"
Funding that does not require a company to issue new shares or reduce existing owners’ percentage of ownership, such as grants, certain loans, licensing deals, or customer prepayments. It matters to investors because it preserves each shareholder’s stake and per-share value—like getting a loan or a gift instead of selling part of the company—while still carrying obligations (repayment, milestones, or restrictions) that can affect future cash flow and growth.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Rocket Pharmaceuticals (RCKT) announce regarding its Priority Review Voucher?
Rocket Pharmaceuticals agreed to sell its Rare Pediatric Disease Priority Review Voucher for $180 million in cash. The voucher was earned after FDA accelerated approval of KRESLADI and its monetization provides non-dilutive capital to support Rocket’s cardiovascular gene therapy pipeline.
How will the $180 million PRV sale affect Rocket Pharmaceuticals’ (RCKT) cash runway?
Rocket states that proceeds from the $180 million PRV sale extend its cash runway into the second quarter of 2028. This longer funding horizon is intended to support key clinical milestones across its cardiovascular gene therapy programs targeting inherited cardiomyopathies.
What is the purpose of Rocket Pharmaceuticals’ (RCKT) PRV sale proceeds?
Rocket plans to use proceeds from the Priority Review Voucher sale to support its prioritized cardiovascular gene therapy pipeline. This includes clinical-stage programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy, which collectively address major inherited cardiomyopathy subtypes.
What conditions must be satisfied before Rocket’s $180 million PRV sale closes?
Closing of the $180 million PRV sale is subject to customary conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The asset purchase agreement also includes standard representations, warranties, covenants and indemnification provisions.
How did Rocket Pharmaceuticals obtain the Rare Pediatric Disease Priority Review Voucher it is selling?
Rocket earned the Rare Pediatric Disease Priority Review Voucher following FDA accelerated approval of KRESLADI, an autologous hematopoietic stem cell gene therapy for pediatric patients with severe LAD-I. The voucher can be used for priority review of another application or sold to another sponsor.
Which Rocket Pharmaceuticals (RCKT) programs are highlighted as benefiting from the PRV monetization?
Rocket cites its prioritized cardiovascular gene therapy pipeline as a key beneficiary of the PRV monetization. Highlighted clinical-stage programs include those in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy, each targeting inherited cardiomyopathy subtypes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal
executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (609 ) 659-8001
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. |
Entry into a Material Definitive Agreement.
|
On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which
the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”). As previously disclosed, the PRV was originally issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™
(marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available
human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant.
Pursuant to the PRV APA, the buyer has agreed to pay the Company $180 million, payable in cash, upon the closing of the sale. The PRV APA contains
customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. The transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The foregoing description of the PRV APA does not purport to be complete and is subject to, and qualified in its entirety, by the full text of the
PRV APA, a copy of which will be filed with Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. The representations, warranties, covenants and agreements contained in the PRV APA were made only for the purposes of
the PRV APA and as of specific dates, are solely for the benefit of the parties to the PRV APA, and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures. The representations and warranties
in the PRV APA were made for the purpose of allocating contractual risk between the parties to the PRV APA instead of establishing these matters as facts. Accordingly, the representations and warranties in the PRV APA are not intended to, and do
not, constitute representations and warranties to any person other than the parties to the PRV APA, including investors and security holders, and should not be relied upon as statements of factual information.
| Item 7.01. |
Regulation FD Disclosure.
|
On April 28, 2026, the Company issued a press release announcing that it had entered into the PRV APA, a copy
of the which is furnished as Exhibit 99.1 hereto.
The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
Forward-Looking Statements
Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or
future events, as well as words such as “believes,” “intends,” “expects,” “plans” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.
Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company’s planned use of proceeds from
the monetization of the PRV and the Company’s expectations regarding its cash runway and financial position will not change. Reference is also made to other factors detailed from time to time in the Company’s periodic reports filed with the
Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the
date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless
required by law.
| Item 9.01. |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
99.1
|
Press Release of Rocket Pharmaceuticals, Inc. dated April 28, 2026.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
Rocket Pharmaceuticals, Inc.
|
||
|
Date: April 28, 2026
|
By:
|
/s/ Martin Wilson
|
|
Martin Wilson
|
||
|
General Counsel and Chief Corporate Officer
|
||
Exhibit 99.1
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline
Cash runway extended into the second quarter of 2028
CRANBURY, NJ – April 28, 2026 – Rocket
Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders
with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).
Rocket has entered into a definitive agreement to sell its PRV for $180 million. The PRV was awarded
following the U.S. Food and Drug Administration (FDA) accelerated approval of KRESLADI™ (marnetegragene autotemcel). The transaction reflects the continued strategic value of PRVs, as well as Rocket’s disciplined approach to capital formation and
allocation in support of its prioritized cardiovascular gene therapy programs.
“The monetization of our PRV, following the FDA approval of KRESLADI, provides meaningful non-dilutive capital and extends our cash runway into the second quarter of
2028,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. “This strengthens our ability to advance key clinical milestones across our cardiovascular gene therapy pipeline, with all programs on track.”
A Rare Pediatric Disease PRV is granted by the FDA to sponsors of approved therapies for certain rare pediatric diseases and may be used to obtain priority review for a
subsequent marketing application or sold to another sponsor. The program was reauthorized in February 2026, extending the availability of vouchers for qualifying therapies and reinforcing its role as an incentive to support development of
treatments for rare pediatric conditions. “We are deeply appreciative of the U.S. government’s continued recognition of the importance of therapeutic development for rare and often devastating pediatric disorders, which comprises an essential part
of Rocket’s mission,” Dr. Shah concluded.
Proceeds from the transaction will support advancement of Rocket’s prioritized cardiovascular gene therapy pipeline, including clinical-stage programs in Danon disease,
PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and BAG3-associated dilated cardiomyopathy (BAG3-DCM). Pro forma for this transaction, Rocket expects its cash runway to extend into the second quarter of 2028.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated biotechnology company advancing gene therapies for rare and devastating cardiovascular diseases, with
additional programs in hematology and immunology. Rocket’s cardiovascular pipeline includes three clinical stage programs that each target one of the major inherited cardiomyopathy subtypes: hypertrophic, arrhythmogenic, and dilated
cardiomyopathies. Together these conditions represent more than 100,000 patients in the U.S. and EU. The Company’s platform is supported by proprietary AAV manufacturing capabilities, multi-year efficacy and safety data in cardiac gene therapy, and
experience treating several cardiac patients across late-stage AAV programs. For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.
Rocket Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as
assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance
on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of
those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s cash runway and financial position, Rocket’s planned use of proceeds from the monetization of the KRESLADI™ PRV, Rocket’s expectations of
our ability to obtain additional funding to conduct our planned research and development efforts, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory
interactions and planned submissions, Rocket’s plans for the advancement of its cardiovascular AAV programs and KRESLADI™, including its planned pivotal trials, and the safety, effectiveness and timing of related pre-clinical studies and clinical
trials, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates and Rocket’s ability to expand its pipeline to target additional indications that are
compatible with its gene therapy technologies. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various important factors, including, without limitation, the results of Rocket’s ongoing and planned clinical trials, Rocket’s dependence on third parties for development, manufacture,
marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s
ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint
ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, our ability to achieve the expected benefits of our portfolio prioritization and strategic restructuring, including extending our cash runway,
Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled “Risk
Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2025, filed February 26, 2026 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events
or otherwise.
Investors
Meg Dodge
mdodge@rocketpharma.com
Media
Kevin Giordano
media@rocketpharma.com